UC-MSC Transplantation for Left Ventricular Dysfunction After AMI

Overview

A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation

Full Title of Study: “Safety and Efficacy Evaluation of Umbilical Cord Mesenchymal Stem Cells Transcatheter Transplantation to Treat Left Ventricular Dysfunction After Acute Myocardial Infarction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 31, 2025

Detailed Description

In this study, 40 patients with cardiac insufficiency after acute myocardial infarction were selected and randomly divided into umbilical cord MSCs transplantation treatment group and non-intervention control group to preliminarily observe the safety and effectiveness of MSCs cell transplantation treatment.

Interventions

  • Biological: UC-MSC
    • 0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5×10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU, at the concentration of 2×10(7) cells/ml.
  • Biological: Control Group
    • Routine treatment without catheter infusion

Arms, Groups and Cohorts

  • Experimental: UC-MSC
    • UC-MSC transplantation
  • Placebo Comparator: Control Group
    • Routine treatment

Clinical Trial Outcome Measures

Primary Measures

  • Safety measured as the number of Major Adverse Cardiac Events (MACE)
    • Time Frame: 12 months
    • Possible adverse events, including adverse events that may occur during angiography and infusion of transplanted cells such as chest pain, arrhythmia, slow blood flow, myocardial injury, fever, allergic reaction, postoperative infection, etc.

Secondary Measures

  • Difference in left ventricular ejection fraction measured by magnetic resonance imaging at baseline and 12 months follow-up
    • Time Frame: 12 months
    • left ventricular ejection fraction measured by magnetic resonance imaging

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with acute extensive anterior myocardial infarction were successfully treated with emergency interventional therapy within 12 hours after onset. LVEF was less than 0.35 by echocardiography 30 days after operation, scar area was more than 25% by MRI, and cardiac function was NYHA III-IV grade. – Fully inform the purpose, method and possible side effects of the test, agree to the test, and sign an informed consent form; – Good compliance, willing to take drugs and follow up according to the requirements of the plan; – Life expectancy exceeds one year. Exclusion Criteria:

  • Those who cannot tolerate cell therapy; – Patients with severe hepatic and renal insufficiency (ALT>1.5 times the upper limit of normal value, Cr >1.5 times the upper limit of normal value); – Patients with malignant tumors or extremely weak patients; – Patients with severe infection; – Patients who are expected to have the second coronary intervention or bypass grafting within 3 months; – Patients with other serious systemic diseases and organ dysfunction; – Patients with cardiogenic shock; – Patients with hemorrhagic diseases; – Researchers believe that anyone who is not suitable for inclusion

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Life Science & Technology
  • Collaborator
    • Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Chengxing Shen, Dr., Principal Investigator, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital
  • Overall Contact(s)
    • Chengxing Shen, +86-18501664545, shencx@sjtu.edu.cn

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.